tiprankstipranks
Tharimmune presents clinical data on TH104 for chronic pruritus
PremiumThe FlyTharimmune presents clinical data on TH104 for chronic pruritus
4M ago
Tharimmune granted patent for delivery of molecularly targeted therapeutics
Premium
The Fly
Tharimmune granted patent for delivery of molecularly targeted therapeutics
4M ago
Tharimmune receives regulatory feedback from EMA for TH104 program
Premium
The Fly
Tharimmune receives regulatory feedback from EMA for TH104 program
4M ago
Tharimmune acquires global license, partners with Intract Pharma
PremiumThe FlyTharimmune acquires global license, partners with Intract Pharma
6M ago
Tharimmune appoints David Jones to Scientific Advisory Board
Premium
The Fly
Tharimmune appoints David Jones to Scientific Advisory Board
8M ago
Tharimmune appoints David Clarke as strategic advisor
Premium
The Fly
Tharimmune appoints David Clarke as strategic advisor
8M ago
Tharimmune announces Type C meeting with FDA for Phase 2 TH104 program
PremiumThe FlyTharimmune announces Type C meeting with FDA for Phase 2 TH104 program
9M ago
Tharimmune announces results of Phase 1 trial of TH104
Premium
The Fly
Tharimmune announces results of Phase 1 trial of TH104
9M ago
Tharimmune Inc trading halted, news pending
Premium
The Fly
Tharimmune Inc trading halted, news pending
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100